- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07290569
Dosebestemmelsesstudie av ORKA-001 hos pasienter med moderat til alvorlig plakkpsoriasis (EVERLAST-B)
En multicenter, randomisert, dobbeltblindet, placebokontrollert, doseringsfinneundersøkelse av ORKA-001 hos deltakere med moderat til alvorlig plakkpsoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey, British Columbia, Canada, V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham, Ontario, Canada, L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough, Ontario, Canada, K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec, Quebec, Canada, G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock, Arkansas, Forente stater, 72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles, California, Forente stater, 90045
- Oruka Therapeutics Investigative Site
-
Los Angeles, California, Forente stater, 90024
- Oruka Therapeutics Investigative Site
-
San Diego, California, Forente stater, 92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami, Florida, Forente stater, 33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows, Illinois, Forente stater, 60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield, Indiana, Forente stater, 46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville, Maryland, Forente stater, 20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens, New York, Forente stater, 11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Oruka Therapeutics Investigative Site
-
Mason, Ohio, Forente stater, 45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland, Oregon, Forente stater, 97201
- Oruka Therapeutics Investigative Site
-
Portland, Oregon, Forente stater, 97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco, Texas, Forente stater, 75033
- Oruka Therapeutics Investigative Site
-
Houston, Texas, Forente stater, 77004
- Oruka Therapeutics Investigative Site
-
Webster, Texas, Forente stater, 77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- Oruka Therapeutics Investigative Site
-
Barcelona, Barcelona, Spania, 08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid, Madrid, Spania, 28002
- Oruka Therapeutics Investigative Site
-
Madrid, Madrid, Spania, 28046
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg, Baden-Wuerrtemberg, Tyskland, 69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim, Lower Saxony, Tyskland, 48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- Oruka Therapeutics Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: (Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentell: (Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentell: (Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Placebo komparator: (Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
Eksperimentell: (Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentell: (Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Placebo komparator: (Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Tidsramme: Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Tidsramme: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Tidsramme: Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Tidsramme: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Tidsramme: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Tidsramme: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Tidsramme: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Tidsramme: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Tidsramme: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- ORKA-001-114
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .